Teva plans sale of troubled Irvine plant
February 11, 2013Manufacturing and Production FDA, Teva
Teva has decided to sell off an injectable pharmaceutical production plant in Irvine, California, that was shut down temporarily for …
Teva appoints Arie Belldegrun to Board of directors
February 11, 2013Manufacturing and Production, Research and Development, Sales and Marketing Arie Belldegrun, Teva
Teva Pharmaceuticals has announced that Dr Arie Belldegrun has been appointed by the directors of Teva to fill a vacancy …
£20m research boost for Scottish biotech
February 11, 2013Research and Development, Sales and Marketing Bayer, BioCity Scotland, Dundee, EFPIA
BioCity Scotland and the University of Dundee are to play key roles in a newly-launched pan-European drug discovery project. In …
Novartis’ Nebraska OTC plant still troubles company
February 11, 2013Manufacturing and Production Novartis, OTC
Novartis has been forced to recall various over-the-counter (OTC) medicines made at its plant in Lincoln, Nebraska, after discovering failures …
Contract research news in brief
February 11, 2013Research and Development Antabio, Aptuit, Argenta, Cross Country Healthcare, ICON, PPD, Quintiles, Verum.de
Icon offers $52m for CCH’s clinical services division, plus updates from PPD, Aptuit, Argenta, Quintiles and Verum.de.
Pharma manufacturing news in brief
February 11, 2013Manufacturing and Production Almac, MeadWestvaco, Rexam, UPS, lilly
A round-up of pharma manufacturing news, including facility updates from MeadWestvaco, Rexam, Almac, UPS and Kemwell Biopharma. MeadWestvaco has said …
Sanofi won’t follow trend for spin-offs
February 8, 2013Sales and Marketing Abbott, Pfizer, Sanofi, Viehbacher
Sanofi’s chief executive Chris Viehbacher says the firm plans to maintain its portfolio of business divisions for the foreseeable future, …
‘Challenging’ Europe slows GSK
February 8, 2013Sales and Marketing GSK, austerity, restructuring
‘Challenging’ economic conditions in Europe are among the factors GlaxoSmithKline is blaming for its sluggish performance, with turnover worldwide down …
Lilly abandons RA drug
February 8, 2013Research and Development, Sales and Marketing RA, lilly, tabalumab
Lilly is abandoning its late-stage trial into investigational rheumatoid arthritis (RA) drug tabalumab but insists the move has nothing to …
Lexapro US loss hits Lundbeck
February 7, 2013Sales and Marketing Danish, Lexapro, Lundbeck
The loss of US patent protection on antidepressant Lexapro has put a significant dent in Lundbeck’s financial performance for 2012. …
Market access: please, no more talk of ‘hurdles’ and ‘obstacles’
February 7, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing barr, market access, pm society
For the UK pharmaceutical industry, biotech or devices firms, any discussion around market access tends to be synonymous with ‘hurdles’ …
Weber Shandwick makes several appointments
February 7, 2013Medical Communications, Sales and Marketing Weber shandwick
PR firm Weber Shandwick has announced a series of new hires to strengthen its leadership across the strategy, creative, media …
‘Sad and shameful day’ for NHS
February 7, 2013Sales and Marketing Cameron, GMC, Mid Staffs, NHS
The Department of Health has pledged its commitment “to a renewed focus on putting patients at the centre of everything …
Bayer/Janssen seek Xa inhibitor antidote
February 6, 2013Research and Development, Sales and Marketing Bayer, Janssen, PRT4445, Xarelto
Bayer HealthCare and Janssen Pharmaceuticals have signed a deal with Portola Pharmaceuticals to evaluate the safety of an investigational antidote …
GSK announces AllTrials support
February 6, 2013Research and Development, Sales and Marketing ABPI, Bad pharma, GSK, Goldacre
GlaxoSmithKline has this morning found itself in the unusual position of being showered with praise by one of its fiercest …
Aesica recruits operations director
February 5, 2013Manufacturing and Production, Research and Development, Sales and Marketing Aesica, CMO
Contract manufacturing organisation (CMO) Aesica has appointed Jarrett Palmer as Operations director of its formulated products business unit business. Palmer …
Sanofi celebrates EU approvals
February 5, 2013Sales and Marketing Lyxumia, Sanofi, Zaltrap, diabetes
Sanofi is celebrating after diabetes treatment Lyxumia (lixisenatide) and metastatic colorectal cancer (mCRC) drug Zaltrap received authorisation in Europe. The …
Recipharm appoints Hans Lennernäs to operating Board
February 5, 2013Manufacturing and Production, Research and Development, Sales and Marketing Recipharm
Recipharm Pharmaceutical Development AB has announced the appointment of Dr Hans Lennernäs to the company’s Board of directors. Lennernäs is …
GP concern over GMC guidance
February 5, 2013Sales and Marketing ABPI, GMC, GP, NHS
The ABPI has ‘warmly’ welcomed the new prescribing guidance from the General Medical Council – but GPs are far from …
SFDA publishes high-risk excipients list
February 5, 2013Manufacturing and Production China, GMP, SFDA
China’s State Food and Drug Administration (SFDA) has published a list of 28 excipients which are considered high-risk and therefore …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
